---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-008950"
form_type: "8-K"
ticker: "NVNO"
cik: "0001661053"
company_name: "enVVeno Medical Corp"
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:43:10.545401+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# enVVeno Medical Reports Positive VenoValve Pivotal Trial Data; 97% of Patients Show Clinical Improvement at Six Months

## Summary
- 97% of VenoValve study patients showed clinical improvement at six months measured by revised Venous Clinical Severity Score (rVCSS).
- 74% of patients achieved clinically meaningful benefit (rVCSS improvement of 3 or more points).
- Average rVCSS improvement per patient was 8 points, over 2.5 times the threshold for clinically meaningful benefit.
- Company on track to file VenoValve FDA approval application (PMA) in Q4 2024.
- Data presented at 2024 American Venous Forum Annual Meeting in Tampa, Florida on March 6, 2024.

## SEC filing metadata
- accession: 0001493152-24-008950
- form_type: 8-K
- ticker: NVNO
- cik: 0001661053
- company_name: enVVeno Medical Corp
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661053/000149315224008950/0001493152-24-008950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661053/000149315224008950/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-008950
- JSON: https://secwatch.observer/filing/0001493152-24-008950.json
- Plain text: https://secwatch.observer/filing/0001493152-24-008950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.